{"id":{"repo_id":"namibia","oai_identifier":"oai:repository.unam.edu.na:11070/4179"},"canonical_url":"https://search.dev.ndltd.org/etd/namibia/oai:repository.unam.edu.na:11070/4179","repository":{"repo_id":"namibia","name":"University of Namibia","base_url":"https://repository.unam.edu.na/server/oai/request"},"display":{"title":"A retrospective review of the utilization of Benzodiazepines and Z-drugs in selected private community pharmacies in Namibia: 2017-2022","abstract":"ackground: Overuse of benzodiazepines and Z-drugs is a considerable global public safety concern. In Namibia, despite the rising burden of mental illnesses, there is a paucity in data regarding the utilization of benzodiazepines and Z-drugs. Aim: The study aimed to determine the patterns and factors associated with the utilization of benzodiazepines and Z-drugs in community pharmacies to guide medicine policy reforms. Methods: A descriptive multicenter longitudinal study as per the World Health Organisation (WHO) medicine utilization design. The consumption data on benzodiazepines and Z-drugs were retrospectively abstracted from the Unisolv® dispensing software in selected pharmacies over a six-year period, 2017-2022. Consequently, key informants were interviewed to identify the drivers of the use of benzodiazepines and Z-drugs. Data were exported to SPSS v25 for analysis of the patterns and factors of use of benzodiazepines and Z-drugs. Results: Of the 10 selected-pharmacies, a total of 867 168 medicines were dispensed over the six-year review period and 2% of these were benzodiazepines and Z-drugs (n=17 840/867 168). Benzodiazepines (BZD) were the most dispensed (56%, n=9993/17 840), mainly to male patients (53.6%). The consumption of benzodiazepines and Z-drugs was highest with Zolpidem (6.07 DDDs/1000 population) compared to other benzodiazepines and Z-drugs. Over 54% of the dispensing encounters of benzodiazepines and Z-drugs were repeat prescriptions of Z-drugs. From 2017 to 2022, the consumption of Z-drugs increased but declined for benzodiazepines. Stakeholders identify the thematic drivers of the use of benzodiazepines and Z-drugs as irrational prescribing, marketing, and patient drug dependency. Conclusion: Whilst, the consumption of benzodiazepines and Z-drugs in Namibia is lower than global estimates, there is an increase in the use of benzodiazepines and Z-drugs in the private health sector. There is a need for a regulatory framework and an education strategy to empower pharmacists’ led interventions towards safe use of new benzodiazepines and Z-drugs in the community pharmacies","abstract_html":"ackground: Overuse of benzodiazepines and Z-drugs is a considerable global public safety concern. In Namibia, despite the rising burden of mental illnesses, there is a paucity in data regarding the utilization of benzodiazepines and Z-drugs. Aim: The study aimed to determine the patterns and factors associated with the utilization of benzodiazepines and Z-drugs in community pharmacies to guide medicine policy reforms. Methods: A descriptive multicenter longitudinal study as per the World Health Organisation (WHO) medicine utilization design. The consumption data on benzodiazepines and Z-drugs were retrospectively abstracted from the Unisolv® dispensing software in selected pharmacies over a six-year period, 2017-2022. Consequently, key informants were interviewed to identify the drivers of the use of benzodiazepines and Z-drugs. Data were exported to SPSS v25 for analysis of the patterns and factors of use of benzodiazepines and Z-drugs. Results: Of the 10 selected-pharmacies, a total of 867 168 medicines were dispensed over the six-year review period and 2% of these were benzodiazepines and Z-drugs (n=17 840/867 168). Benzodiazepines (BZD) were the most dispensed (56%, n=9993/17 840), mainly to male patients (53.6%). The consumption of benzodiazepines and Z-drugs was highest with Zolpidem (6.07 DDDs/1000 population) compared to other benzodiazepines and Z-drugs. Over 54% of the dispensing encounters of benzodiazepines and Z-drugs were repeat prescriptions of Z-drugs. From 2017 to 2022, the consumption of Z-drugs increased but declined for benzodiazepines. Stakeholders identify the thematic drivers of the use of benzodiazepines and Z-drugs as irrational prescribing, marketing, and patient drug dependency. Conclusion: Whilst, the consumption of benzodiazepines and Z-drugs in Namibia is lower than global estimates, there is an increase in the use of benzodiazepines and Z-drugs in the private health sector. There is a need for a regulatory framework and an education strategy to empower pharmacists’ led interventions towards safe use of new benzodiazepines and Z-drugs in the community pharmacies","abstract_has_math":false,"creators":["Iipinge, Taimi"],"institution":"University of Namibia","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Kibuule, Dan"],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024","date_published":"2024","updated_at":"2026-07-27T20:21:56Z","subjects":["Dependency","Defined Daily Dose","Community pharmacies","Benzodiazepine and Z-drugs","Anatomical Therapeutic Chemical","Namibia","University of Namibia"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11070/4179","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Kibuule, Dan"]},{"key":"dc:creator","label":"Author","values":["Iipinge, Taimi"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-10-29T09:30:10Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-10-29T09:30:10Z"]},{"key":"dc:date.issued","label":"Date","values":["2024"]},{"key":"dc:publisher","label":"Institution","values":["University of Namibia"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Dependency","Defined Daily Dose","Community pharmacies","Benzodiazepine and Z-drugs","Anatomical Therapeutic Chemical","Namibia","University of Namibia"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11070/4179"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["A thesis submitted in fulfillment of the requirements for the Degree of Master of Pharmacy in Clinical Pharmacy"]},{"key":"dc:description.abstract","label":"Abstract","values":["ackground: Overuse of benzodiazepines and Z-drugs is a considerable global public safety concern. In Namibia, despite the rising burden of mental illnesses, there is a paucity in data regarding the utilization of benzodiazepines and Z-drugs. Aim: The study aimed to determine the patterns and factors associated with the utilization of benzodiazepines and Z-drugs in community pharmacies to guide medicine policy reforms. Methods: A descriptive multicenter longitudinal study as per the World Health Organisation (WHO) medicine utilization design. The consumption data on benzodiazepines and Z-drugs were retrospectively abstracted from the Unisolv® dispensing software in selected pharmacies over a six-year period, 2017-2022. Consequently, key informants were interviewed to identify the drivers of the use of benzodiazepines and Z-drugs. Data were exported to SPSS v25 for analysis of the patterns and factors of use of benzodiazepines and Z-drugs. Results: Of the 10 selected-pharmacies, a total of 867 168 medicines were dispensed over the six-year review period and 2% of these were benzodiazepines and Z-drugs (n=17 840/867 168). Benzodiazepines (BZD) were the most dispensed (56%, n=9993/17 840), mainly to male patients (53.6%). The consumption of benzodiazepines and Z-drugs was highest with Zolpidem (6.07 DDDs/1000 population) compared to other benzodiazepines and Z-drugs. Over 54% of the dispensing encounters of benzodiazepines and Z-drugs were repeat prescriptions of Z-drugs. From 2017 to 2022, the consumption of Z-drugs increased but declined for benzodiazepines. Stakeholders identify the thematic drivers of the use of benzodiazepines and Z-drugs as irrational prescribing, marketing, and patient drug dependency. Conclusion: Whilst, the consumption of benzodiazepines and Z-drugs in Namibia is lower than global estimates, there is an increase in the use of benzodiazepines and Z-drugs in the private health sector. There is a need for a regulatory framework and an education strategy to empower pharmacists’ led interventions towards safe use of new benzodiazepines and Z-drugs in the community pharmacies"]},{"key":"dc:title","label":"Title","values":["A retrospective review of the utilization of Benzodiazepines and Z-drugs in selected private community pharmacies in Namibia: 2017-2022"]}]}],"canonical_facts":{"dc:contributor.advisor":["Kibuule, Dan"],"dc:creator":["Iipinge, Taimi"],"dc:date.accessioned":["2025-10-29T09:30:10Z"],"dc:date.available":["2025-10-29T09:30:10Z"],"dc:date.issued":["2024"],"dc:description":["A thesis submitted in fulfillment of the requirements for the Degree of Master of Pharmacy in Clinical Pharmacy"],"dc:description.abstract":["ackground: Overuse of benzodiazepines and Z-drugs is a considerable global public safety concern. In Namibia, despite the rising burden of mental illnesses, there is a paucity in data regarding the utilization of benzodiazepines and Z-drugs. Aim: The study aimed to determine the patterns and factors associated with the utilization of benzodiazepines and Z-drugs in community pharmacies to guide medicine policy reforms. Methods: A descriptive multicenter longitudinal study as per the World Health Organisation (WHO) medicine utilization design. The consumption data on benzodiazepines and Z-drugs were retrospectively abstracted from the Unisolv® dispensing software in selected pharmacies over a six-year period, 2017-2022. Consequently, key informants were interviewed to identify the drivers of the use of benzodiazepines and Z-drugs. Data were exported to SPSS v25 for analysis of the patterns and factors of use of benzodiazepines and Z-drugs. Results: Of the 10 selected-pharmacies, a total of 867 168 medicines were dispensed over the six-year review period and 2% of these were benzodiazepines and Z-drugs (n=17 840/867 168). Benzodiazepines (BZD) were the most dispensed (56%, n=9993/17 840), mainly to male patients (53.6%). The consumption of benzodiazepines and Z-drugs was highest with Zolpidem (6.07 DDDs/1000 population) compared to other benzodiazepines and Z-drugs. Over 54% of the dispensing encounters of benzodiazepines and Z-drugs were repeat prescriptions of Z-drugs. From 2017 to 2022, the consumption of Z-drugs increased but declined for benzodiazepines. Stakeholders identify the thematic drivers of the use of benzodiazepines and Z-drugs as irrational prescribing, marketing, and patient drug dependency. Conclusion: Whilst, the consumption of benzodiazepines and Z-drugs in Namibia is lower than global estimates, there is an increase in the use of benzodiazepines and Z-drugs in the private health sector. There is a need for a regulatory framework and an education strategy to empower pharmacists’ led interventions towards safe use of new benzodiazepines and Z-drugs in the community pharmacies"],"dc:identifier.uri":["http://hdl.handle.net/11070/4179"],"dc:language.iso":["en"],"dc:publisher":["University of Namibia"],"dc:subject":["Dependency","Defined Daily Dose","Community pharmacies","Benzodiazepine and Z-drugs","Anatomical Therapeutic Chemical","Namibia","University of Namibia"],"dc:title":["A retrospective review of the utilization of Benzodiazepines and Z-drugs in selected private community pharmacies in Namibia: 2017-2022"],"dc:type":["Thesis"]},"updated_at":"2026-07-27T20:21:56Z"}